MI-Heart ceramides, plasma-994

Test info

  
MI-Heart ceramides, plasma
  
994
  
LAB994
  
MSO
  
N-palmitoyl-sphingosine
N-stearoyl-sphingosine
N-nervonoyl-sphingosine
N-lignoceroyl-sphingosine
Cer(d18:1/16:0)
  

Evaluating for the risk of major adverse cardiovascular events within the next 1 to 5 years.

Specimen

  

Patients should not be receiving Intralipid as it may cause false-elevations in measured ceramides

  
EDTA plasma
  
  
1.0 mL
  
0.5 mL
  

Immediately after collection, mix tube thoroughly by gentle inversion, 8 - 10 times, to prevent clotting

  
  1. Spin
  2. Transfer at least 1.0 mL of plasma into a Screw cap transfer vial/tube (Mayo T914), labelled as EDTA plasma, within two (2) hours of sample collection
  3. Freeze within 8 hours of sample collection
  
  

Frozen (preferred) - 30 days

Refrigerated - 24 hours

Ambient - 8 hours

Performance

  
Mayo Clinic Laboratories (CERAM): R-NX
  
Tu, Fr: 7 a.m.
  
5 - 9 days
  

Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)

Clinical and Interpretive info

  

MI-Heart Ceramide Risk Score:

0-2 Lower risk

3-6 Moderate risk

7-9 Increased risk

10-12 Higher risk

 

Ceramide (16:0): 0.19-0.36 mcmol/L

Ceramide (18:0): 0.05-0.14 mcmol/L

Ceramide (24:1): 0.65-1.65 mcmol/L

Ceramide (16:0)/(24:0): <0.11

Ceramide (18:0)/(24:0): <0.05

Ceramide (24:1)/(24:0): <0.45

 

Reference values have not been established for patients who are <18 years of age.

Note: Ceramide (24:0) alone has not been independently associated with disease and will not be reported.

Ceramide score

Relative risk

Risk category

0-2

1.0

Lower

3-6

1.5

Moderate

7-9

2.2

Increased

10-12

3.5

Higher

  

Plasma ceramides predict risk of myocardial infarction, coronary revascularization, acute coronary syndrome hospitalization and mortality within 5 years.

Risk conferred by plasma ceramides is independent of low-density lipoprotein (LDL) cholesterol, C-reactive protein, LDL particles, and lipoprotein-associated phospholipase A2.

Plasma ceramides can be lowered by diet, exercise, simvastatin, rosuvastatin, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.

Billing

  
0119U
  
Order: 93883-7; Result: 93876-1, 93882-9, 93881-1, 93880-3, 93879-5, 93878-7, 93887-9

Tracking

  
06/29/2020
  
07/10/2020